Howard Capital Management Inc. Buys 2,576 Shares of Boston Scientific Corporation $BSX

Howard Capital Management Inc. grew its stake in Boston Scientific Corporation (NYSE:BSX) by 31.5% in the second quarter, HoldingsChannel.com reports. The fund owned 10,753 shares of the medical equipment provider’s stock after acquiring an additional 2,576 shares during the period. Howard Capital Management Inc.’s holdings in Boston Scientific were worth $1,155,000 at the end of the most recent quarter.

Other institutional investors and hedge funds also recently modified their holdings of the company. 1248 Management LLC bought a new stake in Boston Scientific in the first quarter valued at approximately $26,000. Y.D. More Investments Ltd bought a new stake in shares of Boston Scientific in the 1st quarter valued at $27,000. Sound Income Strategies LLC increased its position in shares of Boston Scientific by 90.9% in the 2nd quarter. Sound Income Strategies LLC now owns 252 shares of the medical equipment provider’s stock valued at $27,000 after buying an additional 120 shares in the last quarter. Princeton Global Asset Management LLC bought a new stake in shares of Boston Scientific in the 2nd quarter valued at $32,000. Finally, Oliver Lagore Vanvalin Investment Group bought a new stake in shares of Boston Scientific in the 2nd quarter valued at $37,000. 89.07% of the stock is owned by institutional investors.

Boston Scientific Stock Down 1.4%

NYSE:BSX opened at $101.00 on Wednesday. The company has a debt-to-equity ratio of 0.49, a quick ratio of 0.82 and a current ratio of 1.37. The company has a market cap of $149.66 billion, a PE ratio of 54.01, a PEG ratio of 2.06 and a beta of 0.61. Boston Scientific Corporation has a 52-week low of $80.64 and a 52-week high of $109.50. The stock has a 50-day simple moving average of $101.07 and a 200 day simple moving average of $102.22.

Boston Scientific (NYSE:BSX) last issued its quarterly earnings results on Wednesday, October 22nd. The medical equipment provider reported $0.75 earnings per share for the quarter, topping the consensus estimate of $0.71 by $0.04. The company had revenue of $5.07 billion during the quarter, compared to analysts’ expectations of $4.97 billion. Boston Scientific had a net margin of 14.43% and a return on equity of 19.74%. The business’s quarterly revenue was up 20.3% on a year-over-year basis. During the same period last year, the business earned $0.63 EPS. Boston Scientific has set its FY 2025 guidance at 3.020-3.040 EPS. Q4 2025 guidance at 0.770-0.790 EPS. On average, sell-side analysts expect that Boston Scientific Corporation will post 2.85 EPS for the current fiscal year.

Analyst Upgrades and Downgrades

Several brokerages have issued reports on BSX. Wells Fargo & Company increased their price target on Boston Scientific from $124.00 to $125.00 and gave the stock an “overweight” rating in a report on Thursday, October 23rd. Leerink Partners increased their price target on Boston Scientific from $127.00 to $128.00 and gave the stock an “outperform” rating in a report on Wednesday, October 1st. Morgan Stanley increased their target price on Boston Scientific from $125.00 to $130.00 and gave the stock an “overweight” rating in a research note on Thursday, October 23rd. Barclays increased their target price on Boston Scientific from $133.00 to $136.00 and gave the stock an “overweight” rating in a research note on Thursday, October 2nd. Finally, Evercore ISI reissued an “outperform” rating on shares of Boston Scientific in a research note on Wednesday, October 22nd. Two analysts have rated the stock with a Strong Buy rating, twenty-one have given a Buy rating and two have issued a Hold rating to the company’s stock. Based on data from MarketBeat.com, the stock presently has a consensus rating of “Buy” and a consensus price target of $123.77.

Insider Activity at Boston Scientific

In related news, EVP Joseph Michael Fitzgerald sold 50,000 shares of the firm’s stock in a transaction on Friday, August 1st. The shares were sold at an average price of $104.63, for a total value of $5,231,500.00. Following the completion of the transaction, the executive vice president owned 178,342 shares of the company’s stock, valued at approximately $18,659,923.46. This trade represents a 21.90% decrease in their ownership of the stock. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through this hyperlink. Also, Director Ellen M. Zane sold 9,990 shares of the firm’s stock in a transaction on Monday, October 27th. The shares were sold at an average price of $101.13, for a total transaction of $1,010,288.70. Following the completion of the transaction, the director directly owned 27,035 shares of the company’s stock, valued at approximately $2,734,049.55. This trade represents a 26.98% decrease in their position. Additional details regarding this sale are available in the official SEC disclosure. Over the last 90 days, insiders sold 180,204 shares of company stock valued at $18,544,846. Corporate insiders own 0.50% of the company’s stock.

About Boston Scientific

Boston Scientific Corporation develops, manufactures, and markets medical devices for use in various interventional medical specialties worldwide. It operates through two segments, MedSurg and Cardiovascular. The company offers devices to diagnose and treat gastrointestinal and pulmonary conditions, such as resolution clips, biliary stent systems, stents and electrocautery enhanced delivery systems, direct visualization systems, digital catheters, and single-use duodenoscopes; devices to treat urological conditions, including ureteral stents, catheters, baskets, guidewires, sheaths, balloons, single-use digital flexible ureteroscopes, holmium laser systems, artificial urinary sphincter, laser system, fiber, and hydrogel systems; and devices to treat neurological movement disorders and manage chronic pain, such as spinal cord stimulator system, proprietary programming software, radiofrequency generator, indirect decompression systems, practice optimization tools, and deep brain stimulation system.